More recently, Bruno et al. successfully used multi genes panel testing for familial melanoma evaluation and, by analyzing 1044 family members and 940 cutaneous melanoma index cases, found that CDKN2A pathogenic variants’ detection rate was 5.53% (52 cases), while adding the variants identified in the other genes, the panel diagnostic sensitivity increases up to 9.47% (89 cases) [104]. The gene discussed is CDKN2A; the disease is melanoma.